 Pandion Therapeutics Inc NASDAQ: PAND shares closed over 133 higher today. What Happened: Pandion a developer of novel therapeutics targeting autoimmune diseases will be acquired by a subsidiary of drug multinational Merck Co, Inc NYSE: MRK, according to a statement issued Thursday. 